Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

MD, MAS

Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Atopic Dermatitis

You can consider decreasing the frequency of trollachinumab to patients who have responded well, but it's definitely not a requirement, and I oftentimes recommend to patients that they don't decrease the frequency because continuous dosing can help to decrease the number of flare ups and decrease the intensity of flare ups when they do have them.